Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1

Kasyapa S. Chitta, Aneel Paulus, Sikander Ailawadhi, Barbara A. Foster, Michael T. Moser, Petr Starostik, Aisha Masood, Taimur Sher, Kena C. Miller, Dan M. Iancu, Jeffrey Conroy, Norma J. Nowak, Sheila N. Sait, David A. Personett, Morton Coleman, Richard R. Furman, Peter Martin, Stephen Maxted Ansell, Kelvin Lee, Asher A Chanan Khan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Understanding the biology of Waldenström macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a patient treated for WM. The cell line secretes human immunoglobulin M (h-IgM) with κ-light chain restriction identical to the primary tumor. The cell line has a modal chromosomal number of 46 and harbors chromosomal changes such as deletion of 6q21, monoallelic deletion of 9p21 (CDKN2A), 13q14 (RB1) and 18q21 (BCL-2), with a consistent amplification of 14q32 (immunoglobulin heavy chain; IgH) identical to its founding tumor sample. The clonal relationship is confirmed by identical CDR3 length and single nucleotide polymorphisms as well as a matching IgH sequence of the cell line and founding tumor. Both also harbor a heterozygous, non-synonymous mutation at amino acid 265 in the MYD88 gene (L265P). The cell line expresses most of the cell surface markers present on the parent cells. Overall, RPCI-WM1 represents a valuable model to study Waldenström macroglobulinemia.

Original languageEnglish (US)
Pages (from-to)387-396
Number of pages10
JournalLeukemia and Lymphoma
Volume54
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Waldenstrom Macroglobulinemia
Cell Line
Neoplasms
Immunoglobulin Heavy Chains
Tumor Cell Line
Single Nucleotide Polymorphism
Immunoglobulin M
Light
Amino Acids
Mutation
Genes

Keywords

  • Cell line
  • Model
  • Preclinical
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Development and characterization of a novel human Waldenström macroglobulinemia cell line : RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1. / Chitta, Kasyapa S.; Paulus, Aneel; Ailawadhi, Sikander; Foster, Barbara A.; Moser, Michael T.; Starostik, Petr; Masood, Aisha; Sher, Taimur; Miller, Kena C.; Iancu, Dan M.; Conroy, Jeffrey; Nowak, Norma J.; Sait, Sheila N.; Personett, David A.; Coleman, Morton; Furman, Richard R.; Martin, Peter; Ansell, Stephen Maxted; Lee, Kelvin; Chanan Khan, Asher A.

In: Leukemia and Lymphoma, Vol. 54, No. 2, 02.2013, p. 387-396.

Research output: Contribution to journalArticle

Chitta, KS, Paulus, A, Ailawadhi, S, Foster, BA, Moser, MT, Starostik, P, Masood, A, Sher, T, Miller, KC, Iancu, DM, Conroy, J, Nowak, NJ, Sait, SN, Personett, DA, Coleman, M, Furman, RR, Martin, P, Ansell, SM, Lee, K & Chanan Khan, AA 2013, 'Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1', Leukemia and Lymphoma, vol. 54, no. 2, pp. 387-396. https://doi.org/10.3109/10428194.2012.713481
Chitta, Kasyapa S. ; Paulus, Aneel ; Ailawadhi, Sikander ; Foster, Barbara A. ; Moser, Michael T. ; Starostik, Petr ; Masood, Aisha ; Sher, Taimur ; Miller, Kena C. ; Iancu, Dan M. ; Conroy, Jeffrey ; Nowak, Norma J. ; Sait, Sheila N. ; Personett, David A. ; Coleman, Morton ; Furman, Richard R. ; Martin, Peter ; Ansell, Stephen Maxted ; Lee, Kelvin ; Chanan Khan, Asher A. / Development and characterization of a novel human Waldenström macroglobulinemia cell line : RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 2. pp. 387-396.
@article{84edc84781c94d109fb1f7fada0bfddd,
title = "Development and characterization of a novel human Waldenstr{\"o}m macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenstr{\"o}m Macroglobulinemia 1",
abstract = "Understanding the biology of Waldenstr{\"o}m macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a patient treated for WM. The cell line secretes human immunoglobulin M (h-IgM) with κ-light chain restriction identical to the primary tumor. The cell line has a modal chromosomal number of 46 and harbors chromosomal changes such as deletion of 6q21, monoallelic deletion of 9p21 (CDKN2A), 13q14 (RB1) and 18q21 (BCL-2), with a consistent amplification of 14q32 (immunoglobulin heavy chain; IgH) identical to its founding tumor sample. The clonal relationship is confirmed by identical CDR3 length and single nucleotide polymorphisms as well as a matching IgH sequence of the cell line and founding tumor. Both also harbor a heterozygous, non-synonymous mutation at amino acid 265 in the MYD88 gene (L265P). The cell line expresses most of the cell surface markers present on the parent cells. Overall, RPCI-WM1 represents a valuable model to study Waldenstr{\"o}m macroglobulinemia.",
keywords = "Cell line, Model, Preclinical, Waldenstr{\"o}m macroglobulinemia",
author = "Chitta, {Kasyapa S.} and Aneel Paulus and Sikander Ailawadhi and Foster, {Barbara A.} and Moser, {Michael T.} and Petr Starostik and Aisha Masood and Taimur Sher and Miller, {Kena C.} and Iancu, {Dan M.} and Jeffrey Conroy and Nowak, {Norma J.} and Sait, {Sheila N.} and Personett, {David A.} and Morton Coleman and Furman, {Richard R.} and Peter Martin and Ansell, {Stephen Maxted} and Kelvin Lee and {Chanan Khan}, {Asher A}",
year = "2013",
month = "2",
doi = "10.3109/10428194.2012.713481",
language = "English (US)",
volume = "54",
pages = "387--396",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Development and characterization of a novel human Waldenström macroglobulinemia cell line

T2 - RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1

AU - Chitta, Kasyapa S.

AU - Paulus, Aneel

AU - Ailawadhi, Sikander

AU - Foster, Barbara A.

AU - Moser, Michael T.

AU - Starostik, Petr

AU - Masood, Aisha

AU - Sher, Taimur

AU - Miller, Kena C.

AU - Iancu, Dan M.

AU - Conroy, Jeffrey

AU - Nowak, Norma J.

AU - Sait, Sheila N.

AU - Personett, David A.

AU - Coleman, Morton

AU - Furman, Richard R.

AU - Martin, Peter

AU - Ansell, Stephen Maxted

AU - Lee, Kelvin

AU - Chanan Khan, Asher A

PY - 2013/2

Y1 - 2013/2

N2 - Understanding the biology of Waldenström macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a patient treated for WM. The cell line secretes human immunoglobulin M (h-IgM) with κ-light chain restriction identical to the primary tumor. The cell line has a modal chromosomal number of 46 and harbors chromosomal changes such as deletion of 6q21, monoallelic deletion of 9p21 (CDKN2A), 13q14 (RB1) and 18q21 (BCL-2), with a consistent amplification of 14q32 (immunoglobulin heavy chain; IgH) identical to its founding tumor sample. The clonal relationship is confirmed by identical CDR3 length and single nucleotide polymorphisms as well as a matching IgH sequence of the cell line and founding tumor. Both also harbor a heterozygous, non-synonymous mutation at amino acid 265 in the MYD88 gene (L265P). The cell line expresses most of the cell surface markers present on the parent cells. Overall, RPCI-WM1 represents a valuable model to study Waldenström macroglobulinemia.

AB - Understanding the biology of Waldenström macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a patient treated for WM. The cell line secretes human immunoglobulin M (h-IgM) with κ-light chain restriction identical to the primary tumor. The cell line has a modal chromosomal number of 46 and harbors chromosomal changes such as deletion of 6q21, monoallelic deletion of 9p21 (CDKN2A), 13q14 (RB1) and 18q21 (BCL-2), with a consistent amplification of 14q32 (immunoglobulin heavy chain; IgH) identical to its founding tumor sample. The clonal relationship is confirmed by identical CDR3 length and single nucleotide polymorphisms as well as a matching IgH sequence of the cell line and founding tumor. Both also harbor a heterozygous, non-synonymous mutation at amino acid 265 in the MYD88 gene (L265P). The cell line expresses most of the cell surface markers present on the parent cells. Overall, RPCI-WM1 represents a valuable model to study Waldenström macroglobulinemia.

KW - Cell line

KW - Model

KW - Preclinical

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84872038376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872038376&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.713481

DO - 10.3109/10428194.2012.713481

M3 - Article

C2 - 22812491

AN - SCOPUS:84872038376

VL - 54

SP - 387

EP - 396

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -